The body's hormone-producing glands
POPULARITY
Categories
269 episodes with endocrine
67 episodes with endocrine
45 episodes with endocrine
31 episodes with endocrine
42 episodes with endocrine
13 episodes with endocrine
10 episodes with endocrine
11 episodes with endocrine
6 episodes with endocrine
4 episodes with endocrine
5 episodes with endocrine
14 episodes with endocrine
6 episodes with endocrine
6 episodes with endocrine
11 episodes with endocrine
7 episodes with endocrine
5 episodes with endocrine
6 episodes with endocrine
6 episodes with endocrine
3 episodes with endocrine
4 episodes with endocrine
6 episodes with endocrine
6 episodes with endocrine
4 episodes with endocrine
3 episodes with endocrine
2 episodes with endocrine
3 episodes with endocrine
3 episodes with endocrine
5 episodes with endocrine
2 episodes with endocrine
5 episodes with endocrine
4 episodes with endocrine
4 episodes with endocrine
2 episodes with endocrine
3 episodes with endocrine
3 episodes with endocrine
In this episode, we review the high-yield topic of Adrenal Cortex and Medulla from the Endocrine section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Angela and Sara Gottfried look at the intricate relationship between trauma, stress responses, and autoimmunity. They discuss how traditional stress responses, such as fight or flight, differ between genders, highlighting the unique ways women may respond to stress through freezing, fawning, or fainting KEY TAKEAWAYS: PINE: The PINE network (Psychology, Immune system, Neurological system, Endocrine system) is particularly vulnerable to toxic stress and trauma Importance of Processing Emotions: Having a supportive network to process emotions is crucial for mitigating long-term consequences of trauma Impact of Puberty on Sensitivity: During puberty, particularly in girls, there is a heightened sensitivity to peer influence, which can lead to emotional dysregulation. Connection Between Emotions and Autoimmunity: There is a potential link between emotional experiences and autoimmune conditions, as suggested by traditions like Ayurveda and insights from figures like Gabor Maté TIMESTAMPS AND KEY TOPICS: [00:03:00] PINE network and trauma connection. [00:05:18] Trauma's impact on hormones. [00:08:16] Autoimmunity and emotional anatomy. VALUABLE RESOURCES Join The High Performance Health Community Click here for discounts on all the products I personally use and recommend A BIG thank you to our sponsors who make the show possible: Full EP 351 Dr Sara Gottfried (Part 2): Trauma, Autoimmunity & Inner Healing https://lnk.to/EP351 ABOUT THE HOST Angela Foster is an award winning Nutritionist, Health & Performance Coach, Speaker and Host of the High Performance Health podcast. A former Corporate lawyer turned industry leader in biohacking and health optimisation for women, Angela has been featured in various media including Huff Post, Runners world, The Health Optimisation Summit, BrainTap, The Women's Biohacking Conference, Livestrong & Natural Health Magazine. Angela is the creator of BioSyncing®️ a blueprint for ambitious entrepreneurial women to biohack their health so they can 10X how they show up in their business and their family without burning out. CONTACT DETAILS Instagram Facebook LinkedIn Disclaimer: The High Performance Health Podcast is for general information purposes only and do not constitute the practice of professional or coaching advice and no client relationship is formed. The use of information on this podcast, or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for medical or other professional advice, diagnosis, or treatment. Users should seek the assistance of their medical doctor or other health care professional for before taking any steps to implement any of the items discussed in this podcast. This Podcast has been brought to you by Disruptive Media. https://disruptivemedia.co.uk/
In this episode, we review the high-yield topic of Thyroid Hormones from the Endocrine section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this episode, we review the high-yield topic of Gestational Diabetes from the Endocrine section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this episode, we take a closer look at tirzepatide, a type 2 diabetes medication also used to help with weight loss. Postmenopause weight gain can be a normal part of aging, and there are some questions about whether medications like tirzepatide could be useful and safe for postmenopausal women. Host Aaron Lohr talks with Maria Daniela Hurtado Andrade, MD, PhD, assistant professor of medicine at Mayo Clinic Florida, and Regina Castaneda, MD, a research fellow at Mayo Clinic College of Medicine & Science. They presented an abstract at ENDO 2025 titled, “One-Year Real-World Weight Loss Outcomes with Tirzepatide in Postmenopausal Women With and Without Hormone Therapy.” Show notes are available at https://www.endocrine.org/podcast/enp105 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast
In this episode, we review the high-yield topic of Metabolic Syndrome from the Endocrine section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this episode, we review the high-yield topic of Craniopharyngioma from the Endocrine section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this episode, we review the high-yield topic of Hypercalcemia from the Endocrine section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Mehlman Qbanks: https://qbanks.mehlmanmedical.com/IG: https://www.instagram.com/mehlman_medical/Telegram: https://mehlmanmedical.com/subscribe/
Mehlman Qbanks: https://qbanks.mehlmanmedical.com/IG: https://www.instagram.com/mehlman_medical/Telegram: https://mehlmanmedical.com/subscribe/
Did you know that approximately 50% of breast cancer patients who have been exposed to an aromatase inhibitor (AI) over time in the metastatic setting develop an ESR1 mutation? Credit available for this activity expires: 10/17/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003008?ecd=bdc_podcast_libsyn_mscpedu
In this episode, we dive deep into the complex and often misunderstood world of endocrine disruption with toxicologist, pharmacologist and endocrine disruption researcher, Chris Borgert PhD. We unpack how the science has evolved, what we actually know about real-world risks, and how public fear has outpaced scientific consensus. From moral panics around masculinity and fertility to the rise of science sensationalism and skewed research incentives, this conversation explores how a nuanced scientific topic became a cultural flashpoint.
Hour 1 -Friday! And the streets are once again ours as we snatch back our soul & freedom from the pawn broker of the weekly grind and here to post bond is Jacob & Tejay. In this segment they further discuss the Big 12 and their problem with tortillas and review TNF Steelers/Bengals.
Ble du litt forvirret nå? Vel, her er forklaringen. Monica har nemlig denne uken lansert en solopodkast og vi har samme plattform på Podplay og da tenkte vi at mange av dere faste lyttere på Biohacking Girls ville ha glede av å vite om dette. Derfor legge vi ved første episode her, og om du liker den kan du gjerne gå inn og høre flere episoder og FOLLOW Hormonpodden: I første episode av Hormonpodden inviterer Monica Øien Dyvi deg inn i et nytt perspektiv på helse der kroppen ikke trenger å fikses, men forstås.Vi snakker om hvordan du kan bli biologisk yngre med peptider, biohacks og livskraft.Du får høre om:Hva hormoner egentlig er og hvorfor de styrer alt fra søvn og energi til vekt og aldring.Hvorfor så mange føler seg slitne, selv med “riktig” livsstil.Hvordan stress, kunstig lys og dårlig søvn forstyrrer kroppens rytmer.Hva biologisk alder betyr og hvordan du kan påvirke den.Hvorfor kroppen din er et økosystem.Sitater fra episoden:“Kroppen din er ikke en maskin, men et økosystem som trenger rytme og kjærlighet for å blomstre.”“Når du lærer å lese signalene kroppen sender, kan du endelig ta styringen tilbake.”Mini-oppdrag:1️⃣ Logg søvn, energi og magefølelse i 7 dager.2️⃣ Kutt én trigger (skjermlys, sukker, vin – du velger).3️⃣ Legg inn 10 minutter ro eller natur hver dag.Gjennom sesongen går vi innom fem hovedområder:Stress & energi, reproduksjon, hjernen & velvære, aldring & reparasjon og metabolsk helse.Link til Podkasten: https://podcasts.apple.com/no/podcast/hormonpodden-biologisk-yngre-med-peptider-biohacks/id1845110326Forskning og kilder nevnt i episoden:• Folkehelseinstituttet (2023): Metabolsk helse og forekomst av insulinresistens i Norge.• Walker, M. (2017). Why We Sleep – Unlocking the Power of Sleep and Dreams. Scribner.• WHO (2022): Endocrine disrupting chemicals and human health.• Bush, Z. (2020). Gut microbiome, soil health, and human resilience.• Sinclair, D. (2019). Lifespan – Why We Age and Why We Don't Have To. Harvard University Press.• Seeds, W. (2021). Peptide Protocols for Human Optimization. Seeds Scientific Research & Performance Institute.Hormonpodden har en instagram konto: @hormonpodden - følg gjerne!!Takk til Torgeir Johansen og Micdrop media for redigering
Ryan Hungerford, MD, Endocrinology-Southern Oregon Internal MedicineCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link: https://forms.office.com/r/FgyGbq5cn1 (or copy & paste into your browser)Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee & Faculty Disclosure: The planning committee and faculty have indicated no relevant financial relationships with an ACCME-defined ineligible company. Their planning contributions were evidence-based and unbiased. All financial relationships (if any) have been mitigated.Original Date: October 16, 2025End Date: October 15, 2026
Ryan Hungerford, MD, Endocrinology-Southern Oregon Internal MedicineCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link: https://forms.office.com/r/FgyGbq5cn1 (or copy & paste into your browser)Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee & Faculty Disclosure: The planning committee and faculty have indicated no relevant financial relationships with an ACCME-defined ineligible company. Their planning contributions were evidence-based and unbiased. All financial relationships (if any) have been mitigated.Original Date: October 16, 2025End Date: October 15, 2026
In the United States, the Food and Drug Administration doesn’t regulate supplements for safety and efficacy, so manufacturers don’t have to disclose their ingredients. We can’t always know for certain what’s in supplements we buy over the counter. Host Aaron Lohr talks with Meghana Pattipati, MD, an endocrine specialist at Ochsner Lafayette General Medical Center in Louisiana. Dr. Pattipati presented a study at ENDO 2025 in San Francisco titled, “Beware of the Hidden Ingredients and Supplement Use in Your Patients With Elevated Testosterone.” The presentation describes a case where a patient unknowingly ingested an ingredient that had a significant endocrine impact. Show notes are available at https://www.endocrine.org/podcast/enp104 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast
This podcast is sponsored by YARAL Pharma. In this episode, we are focusing on the management of hypothyroidism -- a treatable, but not curable condition – and will explore unique challenges for patients with hypothyroidism in long-term care – from tolerability and formulation considerations to consistent dosing and patient needs. Dr. Tamara Ruggles is not affiliated with YARAL Pharma. All views and opinions regarding hypothyroidism are solely her own and are not attributable to YARAL or the Pharmacy Podcast Network. IMPORTANT SAFETY INFORMATION for levothyroxine sodium capsules INDICATION AND USAGE Levothyroxine sodium capsules are L-thyroxine (T4) indicated for adults and pediatric patients 6 years and older with: Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer Limitations of Use: Levothyroxine sodium capsules are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine sodium capsules may induce hyperthyroidism. Levothyroxine sodium capsules are not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis WARNING: NOT FOR THE TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium capsules, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. Contraindications Uncorrected adrenal insufficiency Warnings and Precautions Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate Levothyroxine sodium capsules at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of levothyroxine sodium capsules treatment Prevention of hyperthyroidism or incomplete treatment of hypothyroidism: Proper dose titration and careful monitoring is critical to prevent the persistence of hypothyroidism or the development of hyperthyroidism Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy Decreased bone mineral density associated with thyroid hormone over-replacement: Over-replacement can increase bone reabsorption and decrease bone mineral density. Give the lowest effective dose Adverse Reactions Common adverse reactions with levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic overdosage. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central Nervous System: headache, hyperactivity, nervousness, anxiety, irritability, emotional ability, insomnia Musculoskeletal: tremors, muscle weakness Cardiovascular: palpitations, tachycardia, arrythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest Respiratory: dyspnea Gastrointestinal (GI): diarrhea, vomiting, abdominal cramps, elevations in liver function tests Dermatologic: hair loss, flushing Endocrine: decreased bone mineral density Reproductive: menstrual irregularities, impaired fertility Adverse Reactions in Children Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in children receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in children with resultant compromised adult height. Seizures have been reported rarely with the institution of levothyroxine therapy. Hypersensitivity Reactions Hypersensitivity reactions to inactive ingredients (in this product or other levothyroxine products) have occurred in patients treated with thyroid hormone products. These include urticaria, pruritis, skin rash, flushing, angioedema, various GI symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness and wheezing. Hypersensitivity to levothyroxine itself is not known to occur. Drug Interactions: Many drugs and some foods can exert effects on thyroid hormone pharmacokinetics (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine sodium capsules. Administer at least 4 hours before or after drugs that are known to interfere with absorption. See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism. To report SUSPECTED ADVERSE REACTIONS, contact Yaral Pharma Inc. at 1-866-218-9009, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For Full Prescribing Information, including Boxed Warning, go to www.yaralpharma.com/levothyroxine-pi.
If “balance your hormones” feels like a wellness buzzword, this conversation will be a breath of fresh air. Tara and Elizabeth sit down with Gregory Dodell, MD—board-certified endocrinologist, owner of Central Park Endocrinology, and the brain behind Everything Endocrine on Instagram—to unpack hormones without diet culture. Dr. Dodell shares his evolution to weight-neutral, stigma-free care, explains what hormones actually are, and gives clear, practical guidance for PCOS, thyroid health, cortisol, and when GLP-1 medications make sense. We also cover the lab tests worth asking for, why strength training matters, GLP-1s, and how to navigate the “just lose weight” directive so many patients still hear. Consider this your evidence-informed, compassion-first hormone primer. In this episode: Dr. Dodell's shift from weight-centric training to weight-inclusive care Hormones 101: pituitary → thyroid feedback loops, cortisol basics PCOS made simple: insulin resistance as the foundation “Balance your hormones” claims—what helps and what's hype Lab panels to discuss with your provider (and how often) GLP-1 meds: when they help, red flags, and the importance of monitoring + muscle How to respond when a provider says “just lose weight” Connect with Dr. Dodell: Instagram: https://www.instagram.com/everything_endocrine/ Website: https://www.centralparkendocrinology.com/ Wellness: Rebranded is turning 3 years old! We are hosting a live birthday party on October 23rd in Annapolis and would love for you to join. Learn more about the party here: https://www.eventbrite.com/e/1579100093889?aff=oddtdtcreator Tune into My Entrepreneurial Life hosted by Jen Hawat for a behind the scenes look at building, launching and growing your online business! https://www.jenhowat.com/podcast Connect with us! The Ultimate Self Care Planner: https://elizabethharrisnutrition.ck.page/9e817ab37e Elizabeth Harris, MS, RDN, LDN FB: Health and Healing with Intuitive Eating community https://www.facebook.com/groups/healthandhealingwithintuitiveeating Instagram: https://www.instagram.com/ElizabethHarrisNutrition Free download to break up with diet culture: https://elizabethharrisnutrition.com/invisible-diet Tara De Leon, Master Personal Trainer Email: FitnessTrainer19@hotmail.com Instagram: https://www.instagram.com/tara_de_leon_fitness Join Tara's Newsletter: https://mailchi.mp/5290e3f13e08/email-signup Maria Winters, LCPC, NCC Instagram: https://www.instagram.com/coaching_therapist/ FB: https://www.facebook.com/MWcoachingtherapy Website: www.thecoachingtherapist.com
In this episode, we review the high-yield topic Primary Adrenal Insufficiency from the Endocrine section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Double-Take-Pivotal-Data-Evaluating-PI3K-Inhibitor-Endocrine-Therapy-Regimens-in-mBC/37333/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.
CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Understanding-Endocrine-Resistance-in-HR-HER2-mBC/37323/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.
In this episode, we review the high-yield topic Glucocorticoids from the Endocrine section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
Recently the Endocrine Society held its 12th annual Type 1 Diabetes Fellows Series program, which combines comprehensive education on type 1 diabetes with career development opportunities to build knowledge, practical skills, and a lasting network of colleagues. For this episode, host Aaron Lohr talks with Desmond Schatz, MD, medical director of the Diabetes Institute and director of the Clinical Research Center at the University of Florida. Dr. Schatz gave a talk at the fellows series program titled, “Immunotherapies for Type 1 Diabetes: Need for Early Detection and Screening.” This year’s fellows series program and this episode were made possible by the support of Abbott Diabetes Care, CeQur Corp., Dexcom Inc., Insulet Corp., Breakthrough T1D (formerly the Juvenile Diabetes Research Foundation), Lilly USA, Mankind Pharma Limited, Medtronic Inc., Novo Nordisk Inc., and Vertex Pharmaceuticals Inc. Show notes are available at https://www.endocrine.org/podcast/enp103 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast
Fitness mit M.A.R.K. — Dein Nackt Gut Aussehen Podcast übers Abnehmen, Muskelaufbau und Motivation
Mit den kürzeren Tagen sinkt bei vielen Menschen nicht nur die Energie, sondern auch ihr Vitamin-D-Spiegel. Rutscht er zu sehr ab, hat das Folgen für Leistungsfähigkeit, Immunsystem und Stimmung.Eine neue Studie deutet darauf hin, dass Indoor-Training den im Winter üblichen Vitamin-D-Abfall messbar ausbremst. Kann Deine Fitness-Routine also das Vitamin-D-Supplement ersetzen? Am Ende der Folge bist Du auf Stand und weißt, was das für Dich und Deinen Vitamin-D-Haushalt bedeutet.Außerdem bekommst Du eine klare Strategie an die Hand, um die dunklen Monate von Oktober bis März energiegeladen (und mit vollen Vitamin-D-Speichern) zu überbrücken – statt im Wintermodus auf Reserve zu laufen.____________*WERBUNG: Infos zum Werbepartner dieser Folge und allen weiteren Werbepartnern findest Du hier.____________Tools (Marks Empfehlungen):Vitamin-D-Selbsttest von Medivere.Vitamin-D-Präparat mit 2.000 IE von FormMed (vegane Variante).Weiterführende Inhalte:Download: Ratgeber NahrungsergänzungFolge 502: "Brauchen Sportler Nahrungsergänzung, Herr Ernährungsmediziner?" Mit Niels Schulz-RuhtenbergWissenschaftliche Literatur:Perkin OJ, Davies SE, Hewison M, et al. Exercise without weight loss prevents seasonal decline in vitamin D metabolites: The VitaDEx randomized controlled trial. Advanced Science. 2025;12(22):e2416312.Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chemistry & Biology. 2014;21(3):319-329.Webb AR, Kazantzidis A, Kift RC, Farrar MD, Wilkinson J, Rhodes LE. Meeting vitamin D requirements in white Caucasians at UK latitudes: Providing a choice. Nutrients. 2018;10(4):497.Lin LY, Smeeth L, Langan S, Warren-Gash C. Distribution of vitamin D status in the UK: a cross-sectional analysis of UK Biobank. BMJ Open. 2021;11(1):e038503.de Oliveira LF, de Azevedo LG, da Mota Santana J, de Sales LPC, Pereira-Santos M. Obesity and overweight decreases the effect of vitamin D supplementation in adults: Systematic review and meta-analysis of randomized controlled trials. Reviews in Endocrine and Metabolic Disorders. 2020;21(1):67-76.Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690-693.Drincic AT, Armas LAG, Van Diest EE, Heaney RP. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. Obesity (Silver Spring). 2012;20(7):1444-1448.Ekwaru JP, Zwicker JD, Holick MF, Giovannucci E, Veugelers PJ. The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers. PLoS One. 2014;9(11):e111265.Sun X, Cao ZB, Taniguchi H, Tanisawa K, Higuchi M. Effect of an acute bout of endurance exercise on serum 25(OH)D concentrations in young adults. Journal of Clinical Endocrinology & Metabolism. 2017;102(11):3937-3944.____________Shownotes und Übersicht aller Folgen.Trag Dich in Marks Dranbleiber Newsletter ein.Entdecke Marks Bücher.Folge Mark auf Instagram, Facebook, Strava, LinkedIn. Hosted on Acast. See acast.com/privacy for more information.
An adult patient presents with chronic pain, redness, and swelling in the first metatarsophalangeal joint of the right foot. The clinician notes the joint is warm to the touch with multiple subcutaneous tophi present. Which of the following conditions is MOST likely present? Find it all out in the podcast! Be prepared for the NPTE so that you can pass with flying colors! Check out www.ptfinalexam.com/podcast for more information and to stay up-to-date with our latest courses and projects. #Npte #PT #ptboards #crushtheNPTE #study #studygram #spt #ptstudent #ptlife #sptprobs #physicaltherapystudent #physicaltherapy #physio #physiotherapist #ptlife #ptstudentstudy
Dr. Lora Shahine, renowned fertility specialist, joins Dr. Rena Malik to discuss essential steps for men and women to optimize health before trying to conceive. The conversation covers preconception checkups, the impact of chronic conditions and medications, key lifestyle factors such as nutrition, exercise, sleep, and stress management, as well as the effects of alcohol, smoking, hot tubs, and saunas on fertility. They explore practical strategies for reducing exposure to endocrine-disrupting chemicals in daily life, timing and frequency of intercourse for conception, and demystifying the menstrual cycle and ovulation. The episode also addresses emotional and physical challenges couples face when sex becomes routine, with advice on maintaining intimacy and available medical solutions for sexual dysfunction during the conception journey. Become a Member to Receive Exclusive Content: renamalik.supercast.com Schedule an appointment with me: https://www.renamalikmd.com/appointments ▶️Chapters: 00:00 Introduction00:05 Preconception health checkups00:38 Optimizing health habits01:25 Saunas, hot tubs, fertility02:13 Alcohol recommendations03:39 Endocrine disrupting chemicals05:11 Reducing plastic and toxin exposure09:04 Stopping contraception and ovulation12:14 Understanding menstrual cycles16:09 Timing intercourse for conception17:52 Addressing intimacy challenges Stay connected with Dr. Lora Shahine on social media for daily insights and updates. Don't miss out—follow her now and check out these links! INSTAGRAM - https://www.instagram.com/drlorashahine/?hl=en TIKTOK - https://www.tiktok.com/@drlorashahine?lang=en YOUTUBE - https://www.youtube.com/c/drlorashahine X - https://x.com/drlorashahine?lang=en WEBSITE - https://drlorashahine.com/ Let's Connect!: WEBSITE: http://www.renamalikmd.com YOUTUBE: https://www.youtube.com/@RenaMalikMD INSTAGRAM: http://www.instagram.com/RenaMalikMD TWITTER: http://twitter.com/RenaMalikMD FACEBOOK: https://www.facebook.com/RenaMalikMD/ LINKEDIN: https://www.linkedin.com/in/renadmalik PINTEREST: https://www.pinterest.com/renamalikmd/ TIKTOK: https://www.tiktok.com/RenaMalikMD ------------------------------------------------------ DISCLAIMER: This podcast is purely educational and does not constitute medical advice. The content of this podcast is my personal opinion, and not that of my employer(s). Use of this information is at your own risk. Rena Malik, M.D. will not assume any liability for any direct or indirect losses or damages that may result from the use of information contained in this podcast including but not limited to economic loss, injury, illness or death. Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode, we cover type 1 diabetes and especially insulin delivery systems. Host Aaron Lohr talks with Grazia Aleppo, MD, from Northwestern University’s Feinberg School of Medicine and Diana Isaacs, PharmD, director of education and training in diabetes technology at the Cleveland Clinic. This episode is certified for up to 0.5 AMA PRA Category 1 credits and ABIM MOC points. However, claiming those points requires taking a pre-episode test. Then you must listen to the episode on the Endocrine Society’s Center for Learning website, followed by a post-episode test and evaluation. Please check the show notes for the appropriate link. This episode is supported by educational grants by MannKind Corp. and Insulet Corp. Show notes are available at https://www.endocrine.org/podcast/enp102 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast
Thyroid nodules are common and usually benign, but deciding when and how to intervene is complex. Endocrine surgeons Andrea Gillis, M.D., and Sophie Dream, M.D., along with CRNP Kelly Lovell, explain how they distinguish low-risk cases from those needing treatment. Learn how they help patients choose between monitoring, thermal ablation, and surgery.
Papillary thyroid cancer is the most common type of thyroid cancer, and yet in rare cases, this cancer may originate in locations other than the thyroid glands. In this episode, host Aaron Lohr talks about causes, prevalence, and treatment for papillary thyroid cancer and the rare phenomenon known as ectopic papillary thyroid cancer with Nikita Dhir, MD, of University of Texas Health Science Center at Houston. Dr. Dhir and colleagues presented research at ENDO 2025 in San Francisco titled, “Where Is the Primary Papillary Thyroid Cancer?” Show notes are available at https://www.endocrine.org/podcast/enp101 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast
Dr. Alex Menze and Dr. Christopher J. Klein discuss whether GLP-1RA usage is linked to radiculoplexus neuropathy and common fibular neuropathy. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213916
Dr. Alex Menze talks with Dr. Christopher J. Klein about the clinical presentation, diagnosis, and management of diabetic lumbosacral radiculoplexus neuropathy and common fibular neuropathy in the context of GLP-1RA. Read the related article in Neurology®. Disclosures can be found at Neurology.org.
Join me and special guest Navy Blue on Saturday, August 30 at Loudmouth in Brooklyn, for the ninth iteration of Reel Talk, a Reel Notes movie night. We'll be screening the 1999 animated sci-fi drama The Iron Giant and talking about his latest album, Memoirs in Armour, his production work on Earl Sweatshirt's latest album, Live Laugh Love, and much more. Tickets and more info here.My guest this week is New Jersey-born rapper, producer, director, and humanitarian, GDP. We spoke about Clive Barker's Nightbreed, the magic of independent movie theaters, Solaris, Highest 2 Lowest, Kids, coming up as a rapper and skater in New Jersey, navigating the blog era, looking back on his old music, reflecting on his decade-long break, co-directing a documentary about rapper Tame One, and the creative process behind he and Fatboi Sharif's EP Endocrine, out now via Fused Arrow Records. Come fuck with us.Endocrine is available wherever music is sold, streamed, or stolen. Consider copping directly from GDP's Bandcamp. Follow GDP on Instagram and Twitter: @g6d6p6. Follow Fused Arrow Records on Instagram and Twitter: @fusedarrowrecsMy first book, Reel Notes: Culture Writing on the Margins of Music and Movies, is available now, via 4 PM Publishing. Order a digital copy on Amazon.Reel Notes stands in solidarity with American immigrants against ICE and the oppressed peoples of Palestine, Congo, Sudan, Tigray, and Haiti. Please consider donating to the Coalition for Humane Immigrant Rights, the Palestine Children's Relief Fund, The Palestinian Youth Movement, The Zakat Foundation, HealAfrica, FreeTigray, and/or Hope For Haiti. For information about contacting your representatives to demand a ceasefire, finding protests, and other tools, check out CeasefireToday!Follow me on Instagram (@cinemasai), Twitter (@CineMasai_), Bluesky (@cinemasai.bsky.social), TikTok (@cinemasai), Letterboxd (@CineMasai), and subscribe to my weekly Nu Musique Friday newsletter to stay tapped into all things Dylan Green. Support the show
In this episode of Onc Now, host Jonathan Sackier welcomes Komal Jhaveri, Breast Medical Oncologist and clinical investigator at Memorial Sloan Kettering Cancer Center, New York, USA. Known for her trailblazing work in HER2-positive, HER2-low, and hormone receptor-positive breast cancers, Komal Jhaveri discusses how molecular subtyping, antibody-drug conjugates, and precision trials are reshaping the field. Timestamps 00:00 – Introduction 02:50 – What initially drew Komal into oncology 04:45 – The future of breast cancer care 06:13 – Possibility of personalised treatments for patients 07:40 – Antibody-drug conjugates 09:30 – How we define HER2 status 14:40 – HER2-low disease 17:40 – Targeted therapy combinations 20:54 – Endocrine resistance 23:18 – The realities of implementing new therapies 28:40 – Promising initiatives on the horizon 31:30 – Komal's key takeaways
Join here for expert analysis of the latest clinical trial data in HR-positive MBC and discussion of the clinical implications of these study results. Credit available for this activity expires: 8/18/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002835?ecd=bdc_podcast_libsyn_mscpedu
Send us a textIf our visual scoring is still based on gut feeling, how do we scale precision? In this week's DigiPath Digest, I explored four new AI-focused papers that could reshape how we diagnose prostate, bladder, gastroesophageal, and endocrine cancers.From automated IHC scoring to predicting urethral recurrence post-cystectomy, these studies highlight the growing value—and responsibility—of integrating AI into our pathology workflows.And yes, I also reveal where to get my histology-inspired earrings
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved. https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning. The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive. Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains. https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters. After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms. The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes. The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs. When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act. The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis. As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design. Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery. The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump. Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October. Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module. Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients. The company expects to have training modules available at the same time as the pump's planned launch in 2026. “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive. “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor. We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration. It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said. First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population. MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range. Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components. The company expects a review acceptance decision early in the fourth quarter of 2025. “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation. Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies. This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone. The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030. “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.” “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.” The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year. Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems. The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system. Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM. The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending. Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes. CivicaRx Logo "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities." These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin. The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development." "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs." Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization. "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr. "Civica's work will help to make insulin more affordable for people across the country." Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins. Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status. About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients. Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in. Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load. Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health. Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause. On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour. “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement. “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.” Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health." While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.) Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE. "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down." https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684
After seven years, we have reached our 100th episode! For this, we talk about growth hormone deficiency, about causes, prevalence, why some types may become permanent, available treatments, and the importance of adherence to treatment plans. Host Aaron Lohr talks with Sandro Loche, MD, of Bambino Gesù Children’s Hospital in Rome, Italy. Recently, Dr. Loche and colleagues presented research at ENDO 2025 in San Francisco titled, “Adherence to GH Treatment in the Transition Age: A Prospective Study.” Show notes are available at https://www.endocrine.org/podcast/enp100 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast
Step 1 QBank: step1.mehlmanmedical.comStep 2CK QBank: step2.mehlmanmedical.comStep 3 QBank: step3.mehlmanmedical.comIG: https://www.instagram.com/mehlman_medical/Telegram: https://mehlmanmedical.com/subscribe/
Endocrine disruptors are chemicals that can interfere with the complex system that produces and interacts with our hormones. Research suggests they can affect the reproductive system, our kidneys, and even increase our risk of cancer. There are over 1,000 types of endocrine-disrupting chemicals, according to some estimates, and we are exposed to them daily through things like kitchen utensils and makeup. So how worried should we be about inevitable exposure?Host Elahe Izadi speaks with oncologist Dr. Mikkael Sekeres about the connection between endocrine disruptors and cancer. Dr. Sekeres also shares his advice on steps he takes to avoid these chemicals–and how he puts the risks into perspective.Today's show was produced by Thomas Lu, with help from Rennie Svirnovskiy, who also mixed the episode. It was edited by Ariel Plotnick. Subscribe to The Washington Post here.
In this enlightening episode of Speaking of Pets, we dive deep into the world of endocrine diseases that can affect our beloved furry friends. Our hosts welcome Dr. Liesl Biggie, an expert in veterinary medicine, to discuss important conditions such as diabetes, Cushing's disease, and thyroid disease. We'll unravel the complexities of these ailments, discussing warning signs that pet owners should watch for, such as increased thirst and urination, changes in appetite, and weight fluctuations. Dr. Biggie shares her insights on diagnosis and treatment options, including the latest advancements in medication and management strategies for both cats and dogs. Whether you're a pet owner wanting to learn more about your furry companion's health or simply curious about veterinary medicine, this episode is packed with valuable information and expert advice. Tune in for a blend of education and engaging conversation that will leave you better informed about your pet's well-being! Don't forget to subscribe, like, and share with fellow pet lovers!--What started during the COVID-19 lockdown with one baby gorilla at the Cleveland Zoo has grown into a channel loved by animal fans around the world. I'm a one-person operation—filming, editing, narrating, and sharing the most heartfelt moments of baby gorillas, orangutans, elephants, and other zoo animals. Whether it's Jameela's emotional journey or Clementine's first steps, each video brings you closer to the animals and their stories. If you love watching real animal behavior, learning fun facts, and supporting conservation through storytelling—this is your place! Subscribe to Larry's Animal Safari on YouTube @larrysanimalsafari ---Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents.---All footage is owned by SLA Video Productions.
Podcast summary of articles from the May 2025 edition of the Journal of Emergency Medicine from the American Academy of Emergency Medicine. Topics include HEART score for chest pain, narcotic overdose, airway quality, ED imaging studies, POCUS for soft tissue abscess, and hyperosmolar hyperglycemic state. Guest speaker is Dr. John Bennison.
Featuring an interview with Dr Hope S Rugo, including the following topics: Pharmacologic features of antibody-drug conjugates (ADCs) and implications for their efficacy and toxicity in HR-positive breast cancer (0:00) Clinical and biological factors influencing the sequencing of approved ADCs for HR-positive and triple-negative metastatic breast cancer (4:03) Management of common toxicities with approved ADCs (10:48) Sacituzumab govitecan as first-line therapy for metastatic triple-negative breast cancer (18:17) Trastuzumab deruxtecan in combination with pertuzumab as first-line therapy for HER2-positive metastatic breast cancer (21:09) CME information and select publications
Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, discusses the efficacy and safety of approved and investigational antibody-drug conjugates for endocrine-resistant HR-positive and triple-negative metastatic breast cancer. CME information and select publications here.
Featuring a slide presentation and related discussion from Dr Hope S Rugo, including the following topics: Current treatment landscape for and outcomes in HR-positive, HER2-negative metastatic breast cancer (mBC) (0:00) Trastuzumab deruxtecan for HER2-low and HER2-ultralow mBC (7:49) Sacituzumab govitecan for HR-positive, HER2-negative mBC (20:44) Datopotamab deruxtecan for HR-positive, HER2-negative mBC (27:29) Novel antibody-drug conjugates under investigation for HR-positive mBC (33:19) CME information and select publications
In this episode of The Dairy Nutrition Blackbelt Podcast, Dr. Laura Hernandez from the University of Wisconsin-Madison explores key insights on managing hypocalcemia in dairy cattle. She discusses strategies to prevent both delayed and persistent hypocalcemia, as well as the concept of transient hypocalcemia, highlighting their impact on cow health and lactation performance. Learn about nutritional strategies to optimize calcium homeostasis during the transition period. Listen now on all major platforms!"Delayed hypocalcemia is when you have a normal blood calcium concentration within the first two days postpartum, but then at four days postpartum, it becomes clinical or subclinical hypocalcemia."Meet the guest: Dr. Laura Hernandez is a Professor of Lactation Biology at the University of Wisconsin-Madison, where she directs the Endocrine and Reproductive Physiology Graduate Program. With a Ph.D. in Nutritional Sciences from the University of Arizona, her research focuses on calcium homeostasis during lactation and preventing milk fever in dairy cattle.Click here to read the full research article!Liked this one? Don't stop now — Here's what we think you'll love!What will you learn: (00:00) Highlight(01:47) Introduction(02:09) Dr. Hernandez's background(02:55) Preventing hypocalcemia(05:12) Transient hypocalcemia(08:17) Dietary strategies for prevention(09:15) Calcium binders and phosphorus(12:35) Closing thoughtsThe Dairy Nutrition Blackbelt Podcast is trusted and supported by the innovative companies:* Kemin* Afimilk* Adisseo* Priority IAC- Zinpro- Virtus Nutrition
Please join us to experience the consciousness and healing energies of the InterGalactics to revitalize the endocrine system, hormones, and glands in our body. Known as our inner pharmacopeia, the endocrine organs and hormones released by these glands are vital for our overall health and vitality. We start out with a 50 minute healing session using all the downloaded InterGalactic Healing energies from all four levels to balance, heal, and revitalize the endocrine system. We systematically go through the following endocrine glands:-Hypothalamus-Pituitary-Pineal-Thyroid-Parathyroid-Thymus-Pancreas-Adrenals-Testes/OvariesWe also balance all seven subtle body layers (physical, etheric, emotional, mental, causal, spiritual, and divine) as they relate to the endocrine system.
Recently the Endocrine Society’s Bone and Mineral Special Interest Group discussed the importance of fracture liaison services and how they contribute to an improved quality of life for patients and cost saving for the facility. An important part of the discussion revolved around a recent perspective published in The New England Journal of Medicine titled, “Coordinating Multidisciplinary Care — Improving Outcomes after Fragility Fractures.” The article notes that despite the benefits of fracture liaison services, the lack of reimbursement for those services in the United States is a significant financial barrier, rendering the service underutilized. The article further states that the global burden of hip fractures is expected to double over the next few decades. Are we looking at an impending crisis? What role should fracture liaison services play in reducing treatment gaps and improving post-fracture care? Host Aaron Lohr talks with the three authors of that New England Journal of Medicine perspective: Nicola Napoli, MD, PhD, associate professor of endocrinology and metabolism at Campus Bio-Medico University of Rome, Italy; Peter Ebeling, AO, professor medicine at Monash University in Melbourne, Vic., Australia; and Douglas P. Kiel, MD, professor of medicine at Marcus Institute for Aging Research at Hebrew Senior Life. Show notes are available at https://www.endocrine.org/podcast/enp99 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast
In this powerful solo episode, Darin Olien takes you on a deeply personal, poetic, and science-backed journey into one of the most essential — and overlooked — truths of our time: we are not separate from nature. We are nature. From Yellowstone's trophic cascades to the microbes in your gut, Darin weaves together quantum physics, ecology, indigenous wisdom, and modern biology to reveal the truth of our profound interconnectedness. Every choice we make — what we eat, how we shop, what we wear — sends ripples through the web of life. This episode isn't just about the planet. It's about your soul. It's about understanding that what we do to others, animals, and ecosystems, we do to ourselves — biologically, emotionally, and spiritually. What You'll Learn: 00:00 – What if everything truly is connected? 01:00 – Why harming the planet harms your body 01:50 – Yellowstone wolves & trophic cascades 02:40 – The Earth's $125 trillion ecosystem services 03:30 – How pollution weakens nature — and us 04:20 – Your body is a living ecosystem 05:00 – The cost of sanitizing away our immunity 06:00 – Mirror neurons, empathy, and brain resonance 07:40 – Cambridge Declaration on animal consciousness 08:30 – Factory farming, antibiotic resistance, and emissions 09:15 – Indigenous wisdom: “Mitákuye Oyás'iŋ” – All are related 10:00 – Quantum physics and David Bohm's implicit order 10:30 – Aligning with the web of life through action 11:30 – What your food, clothes, and chemicals say about you 12:45 – Endocrine disruption and teenage hormone crashes 14:20 – Earth as a living organism: Steiner and Gaia theory 16:30 – Why biodynamic farming mirrors natural harmony 18:00 – How your small choices affect the planet 20:00 – Meditation, stillness, and nature as healing 21:30 – Why ego wants to disconnect — and how to stop it 22:30 – Every choice generates life… or cuts it off 23:30 – The ripple effect of conscious living 24:30 – Your lettuce, your sunlight, your sacred connection Thank You to Our Sponsors: Our Place: Toxic-free, durable cookware that supports healthy cooking. Use code DARIN for 10% off at fromourplace.com. Fatty15: Get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/DARIN and using code DARIN at checkout. Find More From Darin: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Podcast: Superlife Key Takeaway: “Every decision you make either aligns with the system of life… or cuts you off from it. There is no separation — only the illusion of it. You are nature. You are the web. And your choices ripple through it all.”
In this episode, I sit down with Dr. Nicole Cain to talk about her integrative, trauma-informed approach to anxiety and mental wellness. We explore how anxiety shows up in the body—through our thoughts, hormones, immune system, and gut—and what it takes to truly heal at the root.Nicole shares insights from her book Panic Proof along with powerful tools like EMDR, hormone testing, and Ayurveda. Whether you're navigating anxiety yourself or supporting someone who is, this conversation is packed with practical, whole-person strategies to find calm and reclaim your mental health.Leave Us A Voice Message! | https://telbee.io/channel/4_b9zzx58wdkuwirqkcxwa/Topics Discussed:What is the root cause of anxiety and how can it be healed naturally?How does gut health affect mental health and anxiety?What is Dr. Nicole Cain's approach to managing anxiety with integrative medicine?What is the connection between hormone imbalances and anxiety symptoms?Sponsored By:Be Well By Kelly Protein Powder & Essentials | Get $10 off your order with PODCAST10 at bewellbykelly.com.AG1 | Get a FREE 1-year supply of Vitamin D3+K2 AND 5 free AG1 Travel Packs with your first subscription at drinkAG1.com/bewell.Jesse & Ben's | Right now, you can visit jesseandbens.com/bewell for a special deal.OneSkin | Visit oneskin.co/BEWELL and use code BEWELL for 15% off your first purchase.Timestamps:00:00:00 - Introduction 00:00:00 – Episode intro with Dr. Nicole Cain00:01:41 – What is anxiety? Root causes explained00:05:49 – Kelly's personal anxiety journey00:09:02 – Understanding the window of tolerance00:10:36 – Anxiety, autonomy, and creative power00:13:22 – Why suppressed emotions intensify anxiety00:14:37 – Dr. Nicole's story of living with anxiety00:19:30 – What is thought anxiety?00:24:32 – Tools to overcome thought anxiety00:26:02 – Endocrine anxiety and stress hormones00:32:21 – Hormonal imbalance, anxiety & HRT00:35:35 – DUTCH testing00:37:21 – Immune system's link to anxiety00:40:34 – Gut-brain axis and mental health00:42:13 – Lifestyle changes for anxiety relief00:43:32 – Dr. Nicole's full intake process00:49:31 – Using Ayurveda and Kapha for anxiety00:51:58 – Exercises to calm anxiety naturally00:57:55 – Brain science: prefrontal cortex vs. lizard brain01:01:55 – Interoception and body awareness01:06:28 – How to become panic proofFurther Listening:Prioritizing Hormonal Health with Dr. Carrie JonesCheck Out Dr. Nicole: InstagramBook - To Shop
© 2020-2025 Ivy Podcast Discovery LLC
